Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
Cabaletta Bio has raised $150.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in May 2026.
Cabaletta Bio's investors include Eli Lilly, Cormorant Asset Management, Adage Capital Management, Redmile Group, Bain Capital Life Sciences.
Cabaletta Bio is headquartered in Philadelphia, United States.
Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
Cabaletta Bio is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cabaletta Bio — Funding & Investors." VCBacked, May 4, 2026, https://www.vcbacked.co/company/cabaletta-bio. Accessed July 19, 2026.
VCBacked. (2026). Cabaletta Bio — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/cabaletta-bio
{{cite web |title=Cabaletta Bio — Funding & Investors |url=https://www.vcbacked.co/company/cabaletta-bio |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated